Another Drug that is close to FDA approval and whi

Another Drug that is close to FDA approval and which has very attracive Market Potential .


RIZAPORT ® for Migraines -Commercial Triptan Market Opportunity

•RIZAPORT® likely to be the first thin film triptan to reach the U.S. market

•Rizatriptan was selected as the drug to deliver via VersaFilm™ because it:

1.Exhibits the highest efficacy data compared to all triptans

2.Exhibits the shortest Tmax, indicating rapid onset of action, which is extremely important for migraine sufferers

3.Highly effective in treatment of migraine attacks in children and adolescents. This sub-group together with the elderly could greatly benefit from RIZAPORT®

•The worldwide market for anti-migraine drugs was estimated to reach approximately $1.7 billion in 2015, of which the sales of triptan drugs, the target market for RIZAPORT®, were estimated at approximately $697 million*

•But the cost of producing RIZAPORT® is low, thus allowing for very high profit margins

•An independent patient survey conducted by Brand Institute found that the majority of patients would be interested in RIZAPORT®
if it becomes available and indicated that they are likely to ask
their physician to prescribe migraine medication in an oral film formulation

•A survey of physicians who treat migraine headaches was conducted and showed that a large majority of these would prescribe a film based migraine treatment